(MENAFN- GlobeNewsWire - Nasdaq) The global antibody conjugate oligonucleotide market is on track for significant growth, driven by increased demand for targeted therapies in oncology, autoimmune ...

Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the 13 Biotech Stocks with Huge Upside Potential. Raymond James has started ...

Fintel reports that on June 11, 2025, Raymond James initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Strong ...

Avidity has been given the go-ahead by the FDA to request accelerated approval of delpacibart braxlosiran—potentially the ...

FUJIFILM Corporation announces the successful validation of the cancer cell-targeting potential of its peptide-oligonucleotide conjugates. This validation resulted from combining oligonucleotides ...

Avidity Biosciences excels in antibody oligonucleotide conjugates, with its stock tripling in the past year due to innovative clinical advancements. Lead asset AOC1001 shows promising results in ...

Avidity Biosciences, Inc.'s stock surged ~650% in the past year, driven by positive developments in its Antibody Oligonucleotide Conjugates (AOCs) for muscular disorders. Key catalysts include a ...

Dublin, May 14, 2025 (GLOBE NEWSWIRE) -- The "Antibody Conjugate Oligonucleotide Market - A Global and Regional Analysis: Focus on Type, Oligonucleotide Type, Target Disease, and Country Analysis ...